ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has successfully confirmed soft-tissue residency properties of its chitosan/platelet-rich plasma (PRP)-based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study.
The Montreal-based clinical-stage regenerative medicine company noted that the meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear.
It said this represents the second orthopedic ORTHO-R soft tissue proof-of-concept application to be successfully confirmed following similar results generated in a previously reported similar study for rotator cuff tear repair.
READ: ChitogenX pursues sales of chitosan as a new revenue initiative in fiscal 3Q and restructures balance sheet
"PRP alone is known to disperse quickly in the joint post delivery, thus suggesting marginal benefits over standard-of-care procedures,” ChitogenX CEO Philippe Deschamps said in a statement.
“Achieving PRP residency a full day post-surgery is another clear demonstration of the residency properties and advantages of our proprietary platform. We are very pleased to see PRP residency confirmed for the second time in a preclinical study model,” he added.
ChitogenX said the results continue to support its contention that ORTHO-R, the company's lead clinical candidate Chitosan/PRP drug combination represents an ideal regenerative medicine delivery mechanism for biologic substances.
“We look forward to reporting the full results of this study over the coming months," Deschamps concluded.
ChitogenX is dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing.
The company is committed to the clinical development of its proprietary ORTHO-R technology platform, a mucoadhesive CHITOSAN-based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various Regenerative Medicine Applications.
Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Contact the author at stephen.gunnion@proactiveinvestors.com